This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Duval M, Klein JP, He WS, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730–3738.
Wong R, Shahjahan M, Wang XM, Thall PF, de Lima M, Khoun I et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005; 11: 108–114.
Lu DP, Dong LJ, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.
Da WM, Wang JB, Zhang JP, Luo RM, Sun Y, Wei ZJ . Tumorablative tailored allogeneic hematopoietic stem cell transplantation in treatment of high risk and refractory leukemia. Chin J Exp Hematol 2009; 17: 219–220.
Da W-M, Da Y. Tumorablative allogeneic hematopoietic stem cell transplantation in the treatment of high-risk and refractory leukemia—new concepts and clinical practice. In: Demirer T (ed). Innovations in Stem Cell Transplantation. INTECH Publisher, Croatia 2013, pp 257–271.
Lu DP . Hematopoietic stem cell transplantation. J Peking Univ 2009; 41: 255–258.
Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010; 115: 3437–3446.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Luo, R., Da, W., Zhang, X. et al. Tumorablative haploidentical hematopoietic cell transplantation for treatment of hematologic malignancy in children. Bone Marrow Transplant 51, 587–588 (2016). https://doi.org/10.1038/bmt.2015.260
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.260